Soleno Therapeutics, Inc. Common Stock
Here’s whether Soleno Therapeutics, Inc. Common Stock (SLNO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.49% over 10 days); 3-month momentum positive (+24.2%). Concerns: trading below the 200-day MA (long-term downtrend); RSI 99 — overbought, elevated pullback risk; weak 1-year return of -24.5%; rising volume on a downtrend (distribution, 2.30x avg). Currently 41.6% off its 52-week high. Score: -1/7.
SLNO is trading below its 200-day MA ($55.82) — a key warning sign the longer-term trend is under pressure. With an RSI of 99.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -24.5% compares to +35.1% for SPY (trailed the market by 59.6%). The current 41.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.